Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent and follow all study requirements and procedures.
• People who have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), including a related type called adenosquamous carcinoma.
• People who have a life expectancy of at least 3 months.
• People whose general physical functioning is rated at 0 or 1 on a standard medical scale (meaning they are fully active or have only minor limitations in physical activity).
• People whose cancer can be measured on scans using a standard set of medical criteria.
• People who have never had radiotherapy, or whose any previous radiotherapy site does not overlap with where new radiotherapy would be given.
• People whose organs (such as liver, kidneys, and blood cells) are working well enough to meet the study's requirements (confirm with trial site for specific levels).
• People of reproductive potential who agree to use an effective form of contraception during the study and for 120 days after the last dose of study treatment.

Who may not be able to join:

• People who have active cancer that has spread to the brain or the membranes surrounding the brain or spinal cord.
• People who have spinal compression fractures that have not been treated with surgery or radiation, or where treated fractures have not been stable for at least 2 weeks before joining.
• People who have a high risk of bleeding in the stomach, intestines, or abdomen.
• People whose cancer-related pain is not well controlled, or where strong pain medication has not yet reached a stable dose.
• People who lost 10% or more of their body weight in the 72 hours before entering the study (compared to their weight when they first signed the consent form).
• People whose general physical functioning score worsened by 1 point or more on the standard medical scale in the 72 hours before entering the study.
• People who are unable to lie flat or still for 10–20 minutes, as required for radiotherapy.
• People who have previously been treated with certain immune system-targeting drugs (such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137, or anti-OX40 antibodies, or similar treatments).
• People who are known to carry an inherited mutation in the BRCA1 or BRCA2 genes.
• People whose cancer has spread to the liver and those liver metastases make up more than 50% of the total liver volume.
• People who have a diagnosed immune system deficiency, or who have been receiving steroid treatment (taken throughout the body, not just applied to the skin) at any point in the 2 years before the first dose of study treatment.
• People who have received chemotherapy, targeted cancer drugs, immunotherapy, or other anti-cancer treatments within 28 days before starting the study, or certain traditional Chinese medicines with anti-cancer indications within 14 days before starting.
• People who have had major surgery within 30 days before the first dose of study treatment.
• People who have received full-dose (radical) radiotherapy within 3 months before the study. Palliative (lower-dose) radiotherapy may be acceptable if it was given at least 2 weeks before starting, and at doses consistent with local treatment standards (confirm with trial site).
• People who need ongoing corticosteroid medication at doses above 10 mg per day of prednisone (or an equivalent dose of another corticosteroid, taken continuously for 7 or more days) in the first 14 days of the study. Exceptions may apply for inhaled or topical steroids, low-dose hormone replacement for adrenal conditions, or short-term use (7 days or fewer) for specific non-immune-related reasons such as allergy prevention.
• People with a persistent, hard-to-correct drop in albumin levels (a protein in the blood).
• People who have received a live virus vaccine within 28 days before the first dose of study treatment.
• People who are known to be HIV-positive or have been diagnosed with AIDS.
• People who have an active infection that requires treatment with systemic (whole-body) medication.
• People with active Hepatitis B or Hepatitis C infection.
• People who have had a heart attack, unstable chest pain, or certain heart or blood vessel procedures or surgeries within 6 months before starting the study.
• People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the study or within 120 days after the last dose of study treatment.
• People who have any other medical condition, past treatment, or lab result that the treating doctor believes would make participation unsafe or unsuitable.
• Any other cases the investigator considers inappropriate for participation.

Important: Always verify eligibility with the trial site directly before applying.